IMMUCELL CORP /DE/ 8-K

What Happened
ImmuCell Corp (ICCC) filed an 8-K on December 29, 2025 announcing it will record a material non‑cash impairment write‑down of certain property, plant and equipment—primarily equipment—during the fourth quarter of 2025. The affected assets are related to production of Re‑Tain®. ImmuCell estimates the non‑cash impact to profit to be approximately $2.3 million, subject to adjustment after review of alternate repurposing and net realizable value during the financial close for the quarter and year ending December 31, 2025. Some, but not all, of the impacted assets will be repurposed to manufacture First Defense®. The company stated there is no specific cash expenditure associated with the write‑down.

Key Details

• Estimated non‑cash impairment: approximately $2.3 million (subject to adjustment).
• Timing: to be recorded in Q4 2025 and finalized as part of year‑end close for the period ending December 31, 2025.
• Assets affected: property, plant and equipment primarily used for Re‑Tain® production; some assets may be repurposed for First Defense®.
• Cash impact: no specific cash outlay tied to the write‑down (non‑cash accounting charge).

Why It Matters
This charge will reduce reported net income for Q4 2025 (and potentially the full 2025 year) by the estimated amount, which investors should expect to see in ImmuCell’s upcoming financial statements. Because the charge is non‑cash, it does not directly affect the company’s cash position or operating cash flow, but it does lower the carrying value of assets on the balance sheet. The potential repurposing of equipment toward First Defense® production could affect future manufacturing capacity and product mix; the final impairment amount may change after the company completes its year‑end valuation and repurposing review.